Home › Research › Topics › randomized
randomized
804 studies tagged randomized, dated 1986-01-01 to 2026-09-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial 2026-09-22
- Varenicline as a Repurposable Drug Candidate for ADRD Prevention 2026-09-20
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims 2026-09-17
Studies
804 studies carry this tag.
Date range
1986 to 2026
Top journals
- Neurology 66
- The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 35
- JAMA 24
- JAMA neurology 23
- Alzheimer's research & therapy 21
333 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
LIGHT will provide insight into the implementation and (cost-)effectiveness of a lifestyle intervention for indicated prevention in a memory clinic setting.
-
Simufilam did not meet co-primary or secondary endpoints in these Phase 3 trials.
-
31/100
Neurodegenerative diseases are progressive disorders that damage and eventually kill neurons in the central nervous system (CNS).
-
EVOKE (ClinicalTrials.gov NCT04777396) and EVOKE+ (NCT04777409) tested whether oral semaglutide, the GLP-1 diabetes/weight-loss drug, could slow early Alzheimer's disease progression in a combined 3,808 participants over up to 156 weeks.
-
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents.
-
In the ADMET2 biomarker subset (n = 44, MPH:21, age:75 years, MMSE:20.2), higher baseline TNF was associated with higher M6 NPI-A [B(SE)= 6.86 (1.71), p = .0003], and multivariable models found lower baseline TNF [B(SE)= 8.28(1.61), p < .001] and higher baseline S100B [B(SE)= -6.41(1.95), p = .002] were associated with lower M6 NPI-A. Exploratory analyses suggested that higher baseline NfL significantly interacted with treatment to predict lower M6 NPI-A [B(SE)= -8.36(4.21), p = .05], only when adjusting for cognition.
-
Alzheimer's disease (AD) is characterized by a progressive cognitive decline involving a multifactorial pathophysiology, including epigenetic dysregulation.
-
In the intention-to-treat analysis, dementia risk was not different between GLP1-RA and DPP4i initiators (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.87–1.04; rates: 6.29 versus 6.64 per 1000 person-years; mean follow-up: 6.54 years); however, continuous GLP1-RA versus DPP4i use was associated with a 21% lower risk (HR 0.79, 95% CI 0.64–0.97; rates: 3.64 versus 4.82; mean follow-up: 2.71 years).
-
The efficacy of acetylcholinesterase inhibitors (AChEI) and memantine (ME) in severe dementia remains uncertain, and real world data are limited.
-
Benefit continued to accrue with ongoing lecanemab treatment through 36 months.
-
The VHA is well-positioned to use a hybrid approach-both telehealth and in-person care-to support the provision of amyloid-targeting therapies for veterans with AD.
-
Data collection began in March 2024. So far 562 people completed a pre-screening online questionnaire, with 190 passing pre-screening of whom 54% met eligibility criteria.
-
Orally dosed D-AIP possessed favourable biostability, pharmacokinetics, and brain region distribution.
-
At 3 years, donanemab slowed disease progression on the Clinical Dementia Rating Scale (CDR)-Sum of Boxes (CDR-SB) in early-start participants versus a weighted ADNI control (-1.2 points; 95 % confidence interval [CI], -1.7, -0.7).
-
Sixty consecutive patients with prodromal or mild AD were screened; 50 were randomized to gamma or sham tACS (mean [SD] age, 67.3 [7.8] years; 25 [50.0%] female and 25 [50.0%] male).
-
Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion.
-
Within the limitations of measuring in vitro equilibrium binding activity of in‐house recombinant antibodies to aqueously extracted Aβ from human postmortem brain tissue, we could not discern a population of Aβ aggregates ( e.g . protofibrils) accessible to one antibody but not the other two.
-
Lecanemab reduced amyloid PET in symptomatic participants with DIAD at Week 24.
-
Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models.
-
Like CP2, C458 and C273 weakly inhibit mtCI, leading to AMPK activation, which triggers a neuroprotective stress response.
-
Of 293 participants screened, 130 were randomized, and 109 (83.8%) completed the study.
-
Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit.
-
Lecanemab was generally well-tolerated during the 6-month lecanemab-only treatment period.
-
TabCAT tests showed good convergent validity with traditional pen-and-paper tests.
-
Overall, 392 patients were enrolled in HARMONY; 49 patients with PDD and 27 patients with DLB were included in the open-label safety analysis, of whom 46 met response criteria and were randomized to receive pimavanserin (n = 22) or placebo (n = 24) during the double-blind period.
-
Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action.
-
There have been 23 studies (completed or reported as ongoing) of multidomain interventions for AD, including 19 RCTs.
-
Amnestic mild cognitive impairment (aMCI) represents a critical prodromal stage of Alzheimer's disease (AD), yet effective therapeutic interventions to prevent or delay this conversion remain an unmet clinical need.
-
The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline.
-
SSRI treatment showed no significant effect on AD dementia progression (hazard ratio = 1.64, 95% confidence interval: 0.61 to 4.38) or cognitive trajectories, regardless of AD pathology.
-
Understanding the neuropathological effects of amyloid β (Aβ)-targeting therapies and amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease is critical for optimising treatment efficacy and patient outcomes.
-
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia).
-
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia).
-
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia).
-
Lecanemab, an anti-amyloid monoclonal antibody, has been approved for treatment of early Alzheimer's disease.
-
Alzheimer's disease (AD) stands as one of the primary neurological disorders affecting humans.
-
A total of 64 patients were enrolled in this ongoing real-world study.
-
43/100
We present the pharmacological properties of EKZ-438, which demonstrate high selectivity for HDAC6 (>8500-fold selectivity for HDAC6 versus all other HDAC6 paralogues), low nanomolar potency (12 nM) for HDAC6, and importantly, CNS-penetrance (unbound brain-to-plasma partition coefficient [Kp,uu,brain] ≥ 0.55) and high oral bioavailability (fraction of dose absorbed [F%] = 70).
-
Zusammenfassung Die Alzheimer Krankheit (AD) ist eine schwere und fortschreitende neurodegenerative Erkrankung des Gehirns, die bislang mit primär nur symptomatisch wirksamen medikamentösen und nicht-medikamentösen Therapieformen als Standardtherapie behandelt wird.
-
Alzheimer's disease (AD), the most prevalent form of dementia, leads to progressive cognitive decline due to pathological hallmarks including amyloid plaques, neurofibrillary tangles, synaptic loss, neuroinflammation, and neuronal cell death, highlighting the urgent need for multitarget therapeutic strategies.
-
GLP-1RA use was associated with lower risk of dementia (HR 0.80, 95% CI 0.71–0.91) and Alzheimer’s disease (HR 0.76, 95% CI 0.59–0.98) compared to DPP4is.
-
A total of 325 participants enrolled and received study drug.
-
Tri demonstrates significant multi-target neuroprotective effects in AD preclinical models.
-
Twenty-nine individuals were enrolled, 3 were women (10.3 %), age 76.3 ± 6 years (mean ± SD).
-
In SURMOUNT-5, treatment with tirzepatide was associated with greater predicted 10-year CVD risk reduction compared with semaglutide.
-
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
-
29/100
Alzheimer disease (AD) is the most common form of dementia, characterized by progressive cognitive decline, memory impairment, synaptic dysfunction, and neurodegeneration.
-
Mild cognitive impairment (MCI) is the in-between stage between healthy cognitive aging and neurodegenerative diseases such as Alzheimer's disease (AD).
-
Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD.
-
Diabetes is a significant modifiable risk factor for cognitive dysfunction.
From across this tag
9 of the 795 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
- Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology
- Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial
- Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies
- Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil
- Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
- Sertraline for the treatment of depression in Alzheimer disease